Sign in to NCBI
Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery.

Kandel D, Bojsen-Møller KN, Svane MS, Samkani A, Astrup A, Holst JJ, Madsbad S, Krarup T.

Am J Clin Nutr. 2019 Jan 9. doi: 10.1093/ajcn/nqy310. [Epub ahead of print]

PMID:
30624666

Similar articles

2.

The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial.

Samkani A, Skytte MJ, Anholm C, Astrup A, Deacon CF, Holst JJ, Madsbad S, Boston R, Krarup T, Haugaard SB.

Lipids Health Dis. 2018 Dec 27;17(1):295. doi: 10.1186/s12944-018-0953-8.

PMID:
30591062
Free PMC Article

Similar articles

3.

Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects.

Samkani A, Skytte MJ, Thomsen MN, Astrup A, Deacon CF, Holst JJ, Madsbad S, Rehfeld JF, Krarup T, Haugaard SB.

Nutrients. 2018 Sep 12;10(9). pii: E1285. doi: 10.3390/nu10091285.

PMID:
30213037
Free PMC Article

Similar articles

4.

A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients.

Samkani A, Skytte MJ, Kandel D, Kjaer S, Astrup A, Deacon CF, Holst JJ, Madsbad S, Rehfeld JF, Haugaard SB, Krarup T.

Br J Nutr. 2018 Apr;119(8):910-917. doi: 10.1017/S0007114518000521.

PMID:
29644957

Similar articles

5.

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.

Lundby-Christensen L, Vaag A, Tarnow L, Almdal TP, Lund SS, Wetterslev J, Gluud C, Boesgaard TW, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S.

BMJ Open. 2016 Feb 25;6(2):e008377. doi: 10.1136/bmjopen-2015-008377.

PMID:
26916685
Free PMC Article

Similar articles

6.

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.

Lundby-Christensen L, Tarnow L, Boesgaard TW, Lund SS, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S, Gluud C, Wetterslev J, Vaag A, Almdal TP.

BMJ Open. 2016 Feb 25;6(2):e008376. doi: 10.1136/bmjopen-2015-008376.

PMID:
26916684
Free PMC Article

Similar articles

7.

Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance.

Eriksen M, Jensen DH, Tribler S, Holst JJ, Madsbad S, Krarup T.

Diabetologia. 2015 May;58(5):920-8. doi: 10.1007/s00125-015-3522-y. Epub 2015 Mar 9.

PMID:
25748606

Similar articles

8.

Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base.

Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, Accurso A, Frassetto L, Gower BA, McFarlane SI, Nielsen JV, Krarup T, Saslow L, Roth KS, Vernon MC, Volek JS, Wilshire GB, Dahlqvist A, Sundberg R, Childers A, Morrison K, Manninen AH, Dashti HM, Wood RJ, Wortman J, Worm N.

Nutrition. 2015 Jan;31(1):1-13. doi: 10.1016/j.nut.2014.06.011. Epub 2014 Jul 16. Review.

PMID:
25287761
Free Article

Similar articles

9.

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report.

Knop FK, Lund A, Madsbad S, Holst JJ, Krarup T, Vilsbøll T.

BMC Res Notes. 2014 May 31;7:326. doi: 10.1186/1756-0500-7-326.

PMID:
24885055
Free PMC Article

Similar articles

10.

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.

Reaney M, Mathieu C, Ostenson CG, Matthaei S, Krarup T, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M, Guerci B.

Health Qual Life Outcomes. 2013 Dec 26;11:217. doi: 10.1186/1477-7525-11-217.

PMID:
24369764
Free PMC Article

Similar articles

11.

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.

Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M.

Diabetes Ther. 2013 Dec;4(2):285-308. doi: 10.1007/s13300-013-0037-8. Epub 2013 Sep 10.

PMID:
24018835
Free PMC Article

Similar articles

12.

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

Kiiskinen U, Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Theodorakis M, Kiljański J, Salaun-Martin C, Sapin H, Guerci B.

Clinicoecon Outcomes Res. 2013 Jul 11;5:355-67. doi: 10.2147/CEOR.S44060. Print 2013.

PMID:
23874113
Free PMC Article

Similar articles

13.

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.

Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M.

Diabetes Metab Syndr Obes. 2013 Apr 26;6:171-85. doi: 10.2147/DMSO.S41827. Print 2013.

PMID:
23667315
Free PMC Article

Similar articles

14.

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study.

Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Guerci B, Kiljanski J, Petto H, Bruhn D, Theodorakis M.

Diabetes Ther. 2012 Nov;3(1):6. doi: 10.1007/s13300-012-0006-7. Epub 2012 Jun 20.

PMID:
22714818
Free PMC Article

Similar articles

15.

Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes.

Hansen M, Nielsen AR, Vilsbøll T, Lund A, Krarup T, Knop FK, Vestergaard H.

Pancreas. 2012 Nov;41(8):1316-8. doi: 10.1097/MPA.0b013e31824d9b93.

PMID:
22647735

Similar articles

16.

Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome?

Krarup T, Krarup T, Hagen C.

Diabetes Metab Res Rev. 2012 Mar;28(3):219-27. doi: 10.1002/dmrr.2262. Review.

PMID:
22162117

Similar articles

17.

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Kielgast U, Krarup T, Holst JJ, Madsbad S.

Diabetes Care. 2011 Jul;34(7):1463-8. doi: 10.2337/dc11-0096. Epub 2011 May 18.

PMID:
21593296
Free PMC Article

Similar articles

18.

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.

Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S.

Diabetes Care. 2011 May;34 Suppl 2:S251-7. doi: 10.2337/dc11-s227. Review. No abstract available.

PMID:
21525464
Free PMC Article

Similar articles

19.

[Reporting adverse reactions and events in randomised clinical trials].

Hemmingsen B, Støy L, Wetterslev J, Tarnow L, Friis KB, Christensen LL, Sales N, Gluud C; Copenhagen Insulin Metformin Therapy Trial-Gruppen.

Ugeskr Laeger. 2010 Aug 30;172(35):2381-4. Danish.

PMID:
20825743

Similar articles

20.

The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency.

Knop FK, Vilsbøll T, Lund A, Krarup T, Holst JJ, Hornum M.

JOP. 2010 Sep 6;11(5):489-91. No abstract available.

PMID:
20818126
Free Article

Similar articles

Supplemental Content

Filters: Manage Filters

Loading ...
You are here: NCBI > Literature > PubMed
Support Center